P11: IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS

• H Auner,
• S Brown,
• K Walker,
• J Kendall,
• B Dawkins,
• D Meads,
• G Morgan,
• M Kaiser,
• M Cook,
• S Roberts,
• C Parrish,
• G Cook

Affiliations

H Auner

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

S Brown

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

K Walker

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

J Kendall

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

B Dawkins

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

D Meads

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

G Morgan

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

M Kaiser

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

M Cook

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

S Roberts

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

C Parrish

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham

G Cook

The Hugh and Josseline Langmuir Centre for Myeloma Research at Imperial College London, Clinical Trials Research Unit and Leeds Institute of Clinical Trials Research at University of Leeds, Academic Unit of Health Economics at Leeds Institute of Health Sciences at University of Leeds, Perlmutter Cancer Center at NYU Langone Health, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham